Free Trial
→ URGENT: If you own a home, please review the map below. (From Paradigm Press) (Ad)tc pixel Free SYRA Stock Alerts

Syra Health (SYRA) Financials

Syra Health logo
$0.71 -0.08 (-9.70%)
As of 10:40 AM Eastern
Compare
Annual Income Statements for Syra Health

Annual Income Statements for Syra Health

This table shows Syra Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.12 -2.94 -3.76 -0.90
Consolidated Net Income / (Loss)		 -2.12 -2.94 -3.76 -0.90
Net Income / (Loss) Continuing Operations		 -2.12 -2.94 -3.76 -0.90
Total Pre-Tax Income 		-2.12 -2.94 -3.76 -0.90
Total Operating Income		 -2.09 -2.89 -3.76 -0.90
Total Gross Profit		 1.06 1.41 1.65 2.49
Total Revenue		 5.62 5.52 7.98 7.23
Operating Revenue		 5.62 5.52 7.98 7.23
Total Cost of Revenue		 4.56 4.10 6.33 4.74
Operating Cost of Revenue		 4.56 4.10 6.33 4.74
Total Operating Expenses		 3.15 4.30 5.42 3.39
Selling, General & Admin Expense		 1.61 1.72 2.05 1.80
Research & Development Expense		 0.00 0.24 0.59 0.07
Depreciation Expense		 0.01 0.05 0.06 0.02
Other Operating Expenses / (Income)		 1.52 2.29 2.72 1.50
Total Other Income / (Expense), net		 -0.03 -0.05 0.01 0.01
Interest Expense		 0.03 0.05 0.02 0.01
Interest & Investment Income		 0.00 0.00 0.02 0.02
Basic Earnings per Share		 ($0.70) ($0.60) ($0.50) ($0.08)
Weighted Average Basic Shares Outstanding		 3.04M 4.88M 7.55M 11.85M
Diluted Earnings per Share		 ($0.70) ($0.60) ($0.50) ($0.08)
Weighted Average Diluted Shares Outstanding		 3.04M 4.88M 7.55M 11.85M
Weighted Average Basic & Diluted Shares Outstanding		 - 5.73M 11.31M 11.34M

Quarterly Income Statements for Syra Health

This table shows Syra Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses		 - - - - - - 0.79 - - - 0.89
Net Income / (Loss) Attributable to Common Shareholders		 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24 0.25 0.34
Consolidated Net Income / (Loss)		 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24 0.25 0.34
Net Income / (Loss) Continuing Operations		 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24 0.25 0.34
Total Pre-Tax Income 		-1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24 0.25 0.30
Total Operating Income		 -1.44 -1.39 -0.43 -0.50 -0.47 -0.06 -0.23 -0.14 0.19 0.25 0.30
Total Gross Profit		 0.30 0.35 0.67 0.33 0.59 0.75 0.55 0.59 0.97 1.07 1.19
Total Revenue		 1.75 1.97 2.25 2.01 1.86 1.95 1.69 1.73 2.27 2.39 2.56
Operating Revenue		 1.75 1.97 2.25 2.01 1.86 1.95 1.69 1.73 2.27 2.39 2.56
Total Cost of Revenue		 1.45 1.62 1.59 1.67 1.27 1.19 1.13 1.14 1.30 1.33 1.37
Operating Cost of Revenue		 1.45 1.62 1.59 1.67 1.27 1.19 1.13 1.14 1.30 1.33 1.37
Total Operating Expenses		 1.74 1.74 1.10 0.84 1.06 0.82 0.79 0.73 0.78 0.81 0.89
Selling, General & Admin Expense		 0.72 0.60 0.44 0.29 0.51 0.45 0.44 0.39 0.40 0.37 0.40
Research & Development Expense		 0.28 0.28 0.03 -0.01 0.04 0.03 0.00 0.00 0.01 0.05 0.05
Depreciation Expense		 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00
Other Operating Expenses / (Income)		 0.74 0.85 0.59 0.54 0.51 0.33 0.34 0.33 0.37 0.39 0.44
Total Other Income / (Expense), net		 -0.00 0.00 0.01 -0.00 0.00 -0.00 0.01 0.00 0.05 -0.00 -0.00
Interest Expense		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Interest & Investment Income		 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.05 0.00 0.00
Income Tax Expense		 - - - - - - 0.00 - - - -0.04
Basic Earnings per Share		 ($0.22) ($0.21) ($0.06) ($0.01) ($0.04) ($0.01) ($0.02) ($0.01) $0.02 $0.02 $0.02
Weighted Average Basic Shares Outstanding		 6.50M 6.60M 7.26M 7.55M 11.59M 11.94M 11.94M 11.85M 11.94M 13.18M 14.19M
Diluted Earnings per Share		 ($0.22) ($0.21) ($0.06) ($0.01) ($0.04) ($0.01) ($0.02) ($0.01) $0.02 $0.02 $0.02
Weighted Average Diluted Shares Outstanding		 6.50M 6.60M 7.26M 7.55M 11.59M 11.94M 11.94M 11.85M 12.78M 13.55M 15.14M
Weighted Average Basic & Diluted Shares Outstanding		 6.42M 6.61M 8.97M 11.31M 11.34M 11.34M 11.34M 11.34M 11.34M 13.84M 13.85M

Annual Cash Flow Statements for Syra Health

This table details how cash moves in and out of Syra Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.10 3.28 -0.88 -0.78
Net Cash From Operating Activities		 -2.24 -2.76 -2.93 -0.45
Net Cash From Continuing Operating Activities		 -2.24 -2.76 -2.93 -0.45
Net Income / (Loss) Continuing Operations		 -2.12 -2.94 -3.76 -0.90
Consolidated Net Income / (Loss)		 -2.12 -2.94 -3.76 -0.90
Depreciation Expense		 0.01 0.05 0.06 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.51 0.03 0.22 0.10
Changes in Operating Assets and Liabilities, net		 -0.67 0.10 0.54 0.33
Net Cash From Investing Activities		 -0.12 -0.02 -0.01 -0.00
Net Cash From Continuing Investing Activities		 -0.12 -0.02 -0.01 -0.00
Purchase of Property, Plant & Equipment		 -0.12 -0.02 -0.01 -0.00
Net Cash From Financing Activities		 2.27 6.05 2.06 -0.33
Net Cash From Continuing Financing Activities		 2.27 6.05 2.06 -0.33
Repayment of Debt		 -2.97 -2.33 -0.41 -0.35
Issuance of Common Equity		 2.32 5.33 2.47 0.01
Cash Interest Paid		 0.01 0.04 0.02 0.01
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Syra Health

This table details how cash moves in and out of Syra Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 -0.04 -1.64 1.10 -0.30 0.10 -0.18 -0.33 -0.36 1.31 -0.80 0.26
Net Cash From Operating Activities		 -0.80 -1.50 -0.41 -0.21 0.16 -0.07 -0.24 -0.29 1.36 -0.72 0.33
Net Cash From Continuing Operating Activities		 -0.80 -1.50 -0.41 -0.21 0.16 -0.07 -0.24 -0.29 1.36 -0.72 0.33
Net Income / (Loss) Continuing Operations		 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24 0.25 0.34
Consolidated Net Income / (Loss)		 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24 0.25 0.34
Depreciation Expense		 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.06 0.07 0.04 0.05 -0.21 0.02 0.02 0.02 0.02 0.02 0.05
Changes in Operating Assets and Liabilities, net		 0.57 -0.20 -0.06 0.23 0.83 -0.04 -0.04 -0.18 1.10 -0.99 -0.06
Net Cash From Financing Activities		 0.76 -0.13 1.52 -0.09 -0.06 -0.11 -0.09 -0.07 -0.05 -0.08 -0.07
Net Cash From Continuing Financing Activities		 0.76 -0.13 1.52 -0.09 -0.06 -0.11 -0.09 -0.07 -0.05 -0.08 -0.07
Repayment of Debt		 -0.09 -0.13 -0.10 -0.09 -0.08 -0.11 -0.09 -0.07 -0.05 -0.08 -0.07
Cash Interest Paid		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Balance Sheets for Syra Health

This table presents Syra Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2.32 4.92 3.68 2.77
Total Current Assets		 1.43 4.78 3.35 2.74
Cash & Equivalents		 0.00 3.28 2.40 1.61
Accounts Receivable		 1.20 1.11 0.68 0.92
Other Current Assets		 0.22 0.39 0.28 0.21
Plant, Property, & Equipment, net		 0.11 0.08 0.03 0.01
Total Noncurrent Assets		 0.78 0.06 0.30 0.03
Other Noncurrent Operating Assets		 0.78 0.06 0.30 0.03
Total Liabilities & Shareholders' Equity		 2.32 4.92 3.68 2.77
Total Liabilities		 1.61 0.91 0.80 0.67
Total Current Liabilities		 1.55 0.91 0.61 0.67
Short-Term Debt		 0.75 0.18 0.15 0.12
Accounts Payable		 0.44 0.46 0.10 0.32
Accrued Expenses		 0.24 0.20 0.23 0.19
Current Deferred Revenue		 - 0.00 0.02 0.02
Other Current Liabilities		 0.12 0.06 0.11 0.03
Total Noncurrent Liabilities		 0.06 0.00 0.19 0.00
Other Noncurrent Operating Liabilities		 0.06 0.00 0.19 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.71 4.01 2.88 2.10
Total Preferred & Common Equity		 0.71 4.01 2.88 2.10
Preferred Stock		 0.00 0.00 0.00 0.00
Total Common Equity		 0.71 4.01 2.88 2.10
Common Stock		 2.84 9.08 12 12
Retained Earnings		 -2.13 -5.06 -8.82 -9.72

Quarterly Balance Sheets for Syra Health

This table presents Syra Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 4.55 3.24 4.43 3.72 3.47 3.26 3.94 3.83 4.23
Total Current Assets		 4.45 2.83 4.06 3.65 3.43 3.21 3.93 3.75 4.16
Cash & Equivalents		 3.24 1.59 2.70 2.49 2.31 1.98 2.92 2.12 2.38
Accounts Receivable		 0.83 0.84 0.88 0.95 0.89 0.93 0.87 1.47 1.52
Other Current Assets		 0.38 0.39 0.48 0.21 0.24 0.31 0.14 0.15 0.26
Plant, Property, & Equipment, net		 0.07 0.06 0.03 0.02 0.01 0.01 0.01 0.01 0.00
Total Noncurrent Assets		 0.03 0.35 0.33 0.05 0.02 0.04 0.01 0.08 0.06
Other Noncurrent Operating Assets		 0.03 0.35 0.33 0.05 0.02 0.04 0.01 0.08 0.06
Total Liabilities & Shareholders' Equity		 4.55 3.24 4.43 3.72 3.47 3.26 3.94 3.83 4.23
Total Liabilities		 1.10 1.15 1.09 1.27 1.06 1.05 1.58 1.20 1.20
Total Current Liabilities		 1.10 0.90 0.88 1.27 1.06 1.05 1.58 1.20 1.20
Short-Term Debt		 0.10 0.11 0.24 0.08 0.09 0.19 0.06 0.07 0.18
Accounts Payable		 0.65 0.50 0.21 0.33 0.56 0.46 0.46 0.32 0.34
Accrued Expenses		 0.32 0.17 0.31 0.21 0.12 0.22 0.29 0.22 0.37
Current Deferred Revenue		 0.01 0.01 0.01 0.60 0.27 0.14 0.75 0.51 0.26
Other Current Liabilities		 0.03 0.11 0.11 0.05 0.02 0.04 0.01 0.08 0.06
Total Noncurrent Liabilities		 0.00 0.24 0.22 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 - 0.24 0.22 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3.45 2.09 3.33 2.46 2.41 2.21 2.36 2.63 3.02
Total Preferred & Common Equity		 3.45 2.09 3.33 2.46 2.41 2.21 2.36 2.63 3.02
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.45 2.09 3.33 2.46 2.41 2.21 2.36 2.63 3.02
Common Stock		 9.96 9.99 12 12 12 12 12 12 12
Retained Earnings		 -6.51 -7.90 -8.32 -9.30 -9.36 -9.59 -9.48 -9.23 -8.88

Annual Metrics And Ratios for Syra Health

This table displays calculated financial ratios and metrics derived from Syra Health's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 8,973,774.00 11,339,169.00
DEI Adjusted Shares Outstanding		 0.00 0.00 8,973,774.00 11,339,169.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.42 -0.08
Growth Metrics		 - - - -
Revenue Growth		 0.00% -1.83% 44.73% -9.47%
EBITDA Growth		 0.00% -37.76% -30.41% 76.13%
EBIT Growth		 0.00% -38.18% -30.38% 75.98%
NOPAT Growth		 0.00% -38.18% -30.38% 75.98%
Net Income Growth		 0.00% -38.72% -27.94% 76.16%
EPS Growth		 0.00% 14.29% 16.67% 84.00%
Operating Cash Flow Growth		 0.00% -22.95% -6.27% 84.73%
Free Cash Flow Firm Growth		 0.00% 0.00% -58.80% 74.64%
Invested Capital Growth		 0.00% -37.00% -30.72% -5.69%
Revenue Q/Q Growth		 0.00% 0.00% 3.11% -3.64%
EBITDA Q/Q Growth		 0.00% 0.00% 11.46% 29.00%
EBIT Q/Q Growth		 0.00% 0.00% 11.40% 28.81%
NOPAT Q/Q Growth		 0.00% 0.00% 11.40% 28.81%
Net Income Q/Q Growth		 0.00% 0.00% 11.55% 29.21%
EPS Q/Q Growth		 0.00% 0.00% 23.08% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 34.47% -19.95%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -36.39%
Invested Capital Q/Q Growth		 0.00% 0.00% -27.18% 42.23%
Profitability Metrics		 - - - -
Gross Margin		 18.90% 25.60% 20.71% 34.43%
EBITDA Margin		 -36.68% -51.47% -46.38% -12.23%
Operating Margin		 -37.20% -52.36% -47.17% -12.51%
EBIT Margin		 -37.20% -52.36% -47.17% -12.51%
Profit (Net Income) Margin		 -37.71% -53.28% -47.10% -12.40%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.36% 101.76% 99.85% 99.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -100.38% -170.19% -339.16% -102.44%
ROIC Less NNEP Spread (ROIC-NNEP)		 -188.09% -92.08% -297.05% -88.36%
Return on Net Nonoperating Assets (RNNOA)		 -197.92% 45.77% 230.07% 66.42%
Return on Equity (ROE)		 -298.29% -124.42% -109.09% -36.02%
Cash Return on Invested Capital (CROIC)		 0.00% -124.79% -302.87% -96.58%
Operating Return on Assets (OROA)		 -90.09% -79.74% -87.53% -28.03%
Return on Assets (ROA)		 -91.31% -81.14% -87.40% -27.78%
Return on Common Equity (ROCE)		 -298.29% -124.42% -109.09% -36.02%
Return on Equity Simple (ROE_SIMPLE)		 -298.29% -73.22% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.46 -2.02 -2.64 -0.63
NOPAT Margin		 -26.04% -36.65% -33.02% -8.76%
Net Nonoperating Expense Percent (NNEP)		 87.71% -78.11% -42.11% -14.08%
Return On Investment Capital (ROIC_SIMPLE)		 - -48.15% -86.94% -28.58%
Cost of Revenue to Revenue		 81.10% 74.40% 79.29% 65.57%
SG&A Expenses to Revenue		 28.69% 31.16% 25.70% 24.95%
R&D to Revenue		 0.00% 4.35% 7.33% 0.94%
Operating Expenses to Revenue		 56.10% 77.96% 67.88% 46.94%
Earnings before Interest and Taxes (EBIT)		 -2.09 -2.89 -3.76 -0.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.06 -2.84 -3.70 -0.88
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 9.39 0.00 1.28 0.46
Price to Tangible Book Value (P/TBV)		 9.39 0.00 1.28 0.46
Price to Revenue (P/Rev)		 1.19 0.00 0.46 0.13
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.09 0.00 2.29 0.00
Enterprise Value to Revenue (EV/Rev)		 1.32 0.00 0.18 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 1.06 0.05 0.05 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 1.05 -0.50 -0.77 -0.75
Leverage Ratio		 3.27 1.53 1.25 1.30
Compound Leverage Factor		 3.31 1.56 1.25 1.29
Debt to Total Capital		 51.38% 4.40% 5.04% 5.26%
Short-Term Debt to Total Capital		 51.38% 4.40% 5.04% 5.26%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 48.62% 95.60% 94.96% 94.74%
Debt to EBITDA		 -0.36 -0.07 -0.04 -0.13
Net Debt to EBITDA		 -0.36 1.09 0.61 1.70
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.51 -0.09 -0.06 -0.18
Net Debt to NOPAT		 -0.51 1.53 0.85 2.37
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 0.59 0.00 -0.90 -1.62
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.92 5.25 5.46 4.06
Quick Ratio		 0.78 4.83 5.01 3.75
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -1.48 -2.35 -0.60
Operating Cash Flow to CapEx		 -1,850.62% -18,091.06% -26,388.56% -418,454.21%
Free Cash Flow to Firm to Interest Expense		 0.00 -27.61 -150.86 -44.97
Operating Cash Flow to Interest Expense		 -78.65 -51.39 -187.95 -33.74
Operating Cash Flow Less CapEx to Interest Expense		 -82.90 -51.68 -188.66 -33.75
Efficiency Ratios		 - - - -
Asset Turnover		 2.42 1.52 1.86 2.24
Accounts Receivable Turnover		 4.68 4.77 8.91 9.04
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 49.94 57.61 150.15 420.93
Accounts Payable Turnover		 10.46 9.13 22.42 22.50
Days Sales Outstanding (DSO)		 78.04 76.52 40.97 40.39
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 34.90 39.97 16.28 16.22
Cash Conversion Cycle (CCC)		 43.14 36.55 24.69 24.17
Capital & Investment Metrics		 - - - -
Invested Capital		 1.46 0.92 0.64 0.60
Invested Capital Turnover		 3.85 4.64 10.27 11.69
Increase / (Decrease) in Invested Capital		 0.00 -0.54 -0.28 -0.04
Enterprise Value (EV)		 7.42 0.00 1.45 -0.53
Market Capitalization		 6.67 0.00 3.70 0.97
Book Value per Share		 $0.23 $0.82 $0.32 $0.19
Tangible Book Value per Share		 $0.23 $0.82 $0.32 $0.19
Total Capital		 1.46 4.20 3.03 2.21
Total Debt		 0.75 0.18 0.15 0.12
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 0.75 -3.10 -2.24 -1.50
Capital Expenditures (CapEx)		 0.12 0.02 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.63 0.78 0.50 0.57
Debt-free Net Working Capital (DFNWC)		 0.63 4.06 2.89 2.18
Net Working Capital (NWC)		 -0.12 3.87 2.74 2.06
Net Nonoperating Expense (NNE)		 0.66 0.92 1.12 0.26
Net Nonoperating Obligations (NNO)		 0.75 -3.10 -2.24 -1.50
Total Depreciation and Amortization (D&A)		 0.03 0.05 0.06 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 11.17% 14.07% 6.22% 7.83%
Debt-free Net Working Capital to Revenue		 11.23% 73.54% 36.23% 30.17%
Net Working Capital to Revenue		 -2.13% 70.19% 34.32% 28.56%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.60) ($0.50) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 4.88M 7.55M 11.85M
Adjusted Diluted Earnings per Share		 $0.00 ($0.60) ($0.50) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 4.88M 7.55M 11.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 5.73M 11.31M 11.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.46 -2.02 -2.64 -0.63
Normalized NOPAT Margin		 -26.04% -36.65% -33.02% -8.76%
Pre Tax Income Margin		 -37.71% -53.28% -47.10% -12.40%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -73.24 -53.79 -241.34 -68.15
NOPAT to Interest Expense		 -51.27 -37.65 -168.94 -47.70
EBIT Less CapEx to Interest Expense		 -77.49 -54.07 -242.05 -68.16
NOPAT Less CapEx to Interest Expense		 -55.52 -37.93 -169.65 -47.71
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Syra Health

This table displays calculated financial ratios and metrics derived from Syra Health's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 5,731,587.00 6,421,632.00 6,612,421.00 8,973,774.00 11,312,544.00 11,339,169.00 11,339,169.00 11,339,169.00 11,339,169.00 11,339,169.00 13,839,169.00
DEI Adjusted Shares Outstanding		 5,731,587.00 6,421,632.00 6,612,421.00 8,973,774.00 11,312,544.00 11,339,169.00 11,339,169.00 11,339,169.00 11,339,169.00 11,339,169.00 13,839,169.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.25 -0.22 -0.06 -0.06 -0.04 -0.01 -0.02 -0.01 0.02 0.02 0.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 47.46% 101.14% 42.50% 13.62% 6.02% -1.19% -25.09% -13.59% 22.38% 23.03% 51.50%
EBITDA Growth		 -87.67% -77.93% -21.99% 49.23% 67.41% 95.84% 43.78% 73.02% 141.16% 541.26% 232.61%
EBIT Growth		 -86.44% -77.35% -25.04% 49.13% 67.22% 95.46% 45.87% 72.96% 140.35% 498.32% 229.22%
NOPAT Growth		 -86.44% -77.35% -25.04% 49.13% 67.22% 95.46% 45.87% 72.96% 157.64% 669.03% 312.29%
Net Income Growth		 -84.13% -73.18% -17.82% 49.32% 67.36% 95.43% 45.90% 73.32% 151.03% 493.49% 252.55%
EPS Growth		 -22.22% -16.67% 25.00% 93.75% 81.82% 95.24% 66.67% 0.00% 150.00% 300.00% 200.00%
Operating Cash Flow Growth		 -1,676.99% -155.79% -11.93% 87.78% 119.76% 95.18% 40.89% -34.68% 760.73% -891.71% 235.83%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 95.30% 123.53% 124.64% 15.09% 1,276.21% -136.25% -118.26%
Invested Capital Growth		 0.00% 0.00% 0.00% -30.72% -86.76% -68.16% -51.71% -5.69% -1,311.55% 198.42% 94.33%
Revenue Q/Q Growth		 -0.78% 12.40% 14.40% -10.94% -7.42% 4.76% -13.27% 2.73% 31.11% 5.32% 6.80%
EBITDA Q/Q Growth		 -46.99% 4.08% 70.62% -22.57% 5.63% 87.74% -296.60% 41.19% 243.99% 31.39% 19.18%
EBIT Q/Q Growth		 -46.42% 3.71% 69.15% -16.96% 5.65% 86.66% -267.60% 41.57% 240.78% 31.72% 19.25%
NOPAT Q/Q Growth		 -46.42% 3.71% 69.15% -16.96% 5.65% 86.66% -267.60% 41.57% 301.11% 31.72% 37.14%
Net Income Q/Q Growth		 -45.39% 3.92% 69.97% -20.80% 6.37% 86.53% -255.21% 40.43% 279.07% 3.84% 37.71%
EPS Q/Q Growth		 -37.50% 4.55% 71.43% 83.33% -300.00% 75.00% -100.00% 50.00% 300.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 54.43% -87.73% 72.51% 48.05% 173.69% -145.80% -237.08% -18.37% 570.95% -152.77% 146.17%
Free Cash Flow Firm Q/Q Growth		 0.00% -20.01% 25.98% 94.11% 10.30% 701.25% -22.50% -120.31% 1,342.51% -118.53% 60.96%
Invested Capital Q/Q Growth		 -66.19% 97.27% 42.66% -27.18% -93.54% 374.50% 116.33% 42.23% -182.99% 216.87% 40.87%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 17.11% 17.77% 29.66% 16.69% 31.71% 38.69% 32.85% 34.09% 42.72% 44.53% 46.34%
EBITDA Margin		 -81.69% -69.71% -17.90% -24.64% -25.11% -2.94% -13.43% -7.69% 8.45% 10.54% 11.76%
Operating Margin		 -82.40% -70.59% -19.03% -25.00% -25.48% -3.25% -13.75% -7.82% 8.40% 10.51% 11.73%
EBIT Margin		 -82.40% -70.59% -19.03% -25.00% -25.48% -3.25% -13.75% -7.82% 8.40% 10.51% 11.73%
Profit (Net Income) Margin		 -82.58% -70.58% -18.53% -25.14% -25.42% -3.27% -13.38% -7.76% 10.60% 10.45% 13.48%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 115.00%
Interest Burden Percent		 100.21% 99.99% 97.35% 100.54% 99.77% 100.69% 97.30% 99.20% 126.18% 99.47% 99.89%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -15.00%
Return on Invested Capital (ROIC)		 -2,259.57% -1,141.09% -236.20% -179.76% -820.82% -45.39% -111.49% -64.04% 0.00% 218.86% 194.75%
ROIC Less NNEP Spread (ROIC-NNEP)		 -2,231.77% -1,084.74% -226.65% -174.02% -815.74% -44.34% -108.50% -61.92% 0.00% 218.92% 194.77%
Return on Net Nonoperating Assets (RNNOA)		 2,030.96% 767.32% 167.21% 134.78% 767.20% 36.40% 83.14% 46.54% 0.00% -185.23% -148.57%
Return on Equity (ROE)		 -228.61% -373.77% -68.98% -44.98% -53.62% -8.99% -28.35% -17.49% -7.60% 33.62% 46.18%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -302.87% -959.84% -151.05% -67.57% -96.58% 0.00% -80.36% 33.69%
Operating Return on Assets (OROA)		 -110.06% -154.10% -66.60% -46.39% -49.81% -7.80% -26.83% -17.52% 16.75% 23.28% 28.07%
Return on Assets (ROA)		 -110.29% -154.09% -64.84% -46.64% -49.70% -7.85% -26.11% -17.38% 21.13% 23.16% 32.24%
Return on Common Equity (ROCE)		 -228.61% -373.77% -68.98% -44.98% -53.62% -8.99% -28.35% -17.49% -7.60% 33.62% 46.18%
Return on Equity Simple (ROE_SIMPLE)		 -104.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.01 -0.97 -0.30 -0.35 -0.33 -0.04 -0.16 -0.09 0.19 0.25 0.35
NOPAT Margin		 -57.68% -49.41% -13.32% -17.50% -17.84% -2.27% -9.63% -5.48% 8.40% 10.51% 13.49%
Net Nonoperating Expense Percent (NNEP)		 -27.80% -56.35% -9.55% -5.74% -5.07% -1.05% -2.99% -2.12% 1.90% -0.06% -0.02%
Return On Investment Capital (ROIC_SIMPLE)		 -28.49% -44.11% -8.41% -11.58% -13.09% -1.77% -6.78% -4.29% 7.88% 9.30% 10.77%
Cost of Revenue to Revenue		 82.89% 82.23% 70.34% 83.31% 68.29% 61.31% 67.15% 65.91% 57.28% 55.47% 53.66%
SG&A Expenses to Revenue		 40.94% 30.36% 19.62% 14.64% 27.52% 23.33% 26.31% 22.70% 17.60% 15.64% 15.54%
R&D to Revenue		 15.84% 14.11% 1.55% -0.26% 2.00% 1.53% 0.05% 0.01% 0.30% 1.98% 1.83%
Operating Expenses to Revenue		 99.51% 88.36% 48.69% 41.69% 57.19% 41.93% 46.61% 41.92% 34.32% 34.03% 34.61%
Earnings before Interest and Taxes (EBIT)		 -1.44 -1.39 -0.43 -0.50 -0.47 -0.06 -0.23 -0.14 0.19 0.25 0.30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.43 -1.37 -0.40 -0.49 -0.47 -0.06 -0.23 -0.13 0.19 0.25 0.30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.29 4.20 0.84 1.28 1.20 0.51 0.46 0.46 1.03 2.74 4.03
Price to Tangible Book Value (P/TBV)		 2.29 4.20 0.84 1.28 1.20 0.51 0.46 0.46 1.03 2.74 4.03
Price to Revenue (P/Rev)		 1.30 1.24 0.36 0.46 0.36 0.15 0.14 0.13 0.32 0.89 1.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 55.29 17.37
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.81% 5.76%
Enterprise Value to Invested Capital (EV/IC)		 15.37 11.95 0.40 2.29 12.77 0.00 0.00 0.00 0.00 8.90 12.17
Enterprise Value to Revenue (EV/Rev)		 0.78 1.04 0.04 0.18 0.06 0.00 0.00 0.00 0.00 0.64 1.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 61.47 16.31
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 69.28 16.44
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 69.28 16.44
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 47.20 14.54
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 47.70
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.03 0.05 0.07 0.05 0.03 0.04 0.09 0.06 0.03 0.03 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.91 -0.71 -0.74 -0.77 -0.94 -0.82 -0.77 -0.75 -1.09 -0.85 -0.76
Leverage Ratio		 1.32 1.55 1.33 1.25 1.40 1.49 1.39 1.30 1.59 1.45 1.43
Compound Leverage Factor		 1.32 1.55 1.29 1.26 1.40 1.50 1.35 1.29 2.01 1.44 1.43
Debt to Total Capital		 2.79% 5.18% 6.73% 5.04% 2.96% 3.47% 7.88% 5.26% 2.56% 2.65% 5.60%
Short-Term Debt to Total Capital		 2.79% 5.18% 6.73% 5.04% 2.96% 3.47% 7.88% 5.26% 2.56% 2.65% 5.60%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.21% 94.82% 93.27% 94.96% 97.04% 96.53% 92.12% 94.74% 97.44% 97.35% 94.40%
Debt to EBITDA		 -0.03 -0.03 -0.06 -0.04 -0.03 -0.06 -0.15 -0.13 -0.28 0.85 0.29
Net Debt to EBITDA		 0.89 0.36 0.59 0.61 0.88 1.56 1.44 1.70 12.70 -24.37 -3.60
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.04 -0.04 -0.08 -0.06 -0.04 -0.08 -0.21 -0.18 -0.37 0.96 0.30
Net Debt to NOPAT		 1.26 0.51 0.83 0.85 1.24 2.16 2.01 2.37 17.03 -27.46 -3.63
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.47 2.67 1.20 2.02 0.42 0.01 -0.68 -0.71 0.37 3.38 6.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.04 3.14 4.63 5.46 2.88 3.25 3.05 4.06 2.48 3.13 3.47
Quick Ratio		 3.69 2.70 4.08 5.01 2.71 3.02 2.75 3.75 2.40 3.00 3.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.32 -1.59 -1.17 -0.07 -0.06 0.37 0.29 -0.06 0.73 -0.14 -0.05
Operating Cash Flow to CapEx		 -14,250.67% -27,371.94% 0.00% 0.00% 0.00% 0.00% 0.00% -270,272.90% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -324.05 -425.18 -517.94 -12.51 -19.22 96.70 151.79 -13.73 296.45 -61.01 -39.03
Operating Cash Flow to Interest Expense		 -196.41 -403.13 -182.39 -38.84 49.00 -18.79 -128.25 -67.60 553.19 -324.20 245.26
Operating Cash Flow Less CapEx to Interest Expense		 -197.78 -404.60 -182.39 -38.84 49.00 -18.79 -128.25 -67.62 553.19 -324.20 245.26
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.34 2.18 3.50 1.86 1.95 2.40 1.95 2.24 1.99 2.22 2.39
Accounts Receivable Turnover		 7.34 8.40 0.00 8.91 9.12 9.33 8.28 9.04 8.42 6.87 7.33
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 84.38 117.50 0.00 150.15 174.68 215.79 342.40 420.93 577.13 818.65 1,312.52
Accounts Payable Turnover		 6.99 10.56 0.00 22.42 12.66 10.82 15.77 22.50 12.08 11.18 13.00
Days Sales Outstanding (DSO)		 49.70 43.45 0.00 40.97 40.02 39.10 44.07 40.39 43.35 53.16 49.78
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 52.19 34.55 0.00 16.28 28.82 33.74 23.15 16.22 30.21 32.64 28.07
Cash Conversion Cycle (CCC)		 -2.49 8.90 0.00 24.69 11.20 5.37 20.92 24.17 13.13 20.51 21.71
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.31 0.61 0.87 0.64 0.04 0.19 0.42 0.60 -0.50 0.58 0.82
Invested Capital Turnover		 39.17 23.09 17.73 10.27 46.02 19.98 11.58 11.69 -33.46 20.83 14.44
Increase / (Decrease) in Invested Capital		 0.31 0.61 0.87 -0.28 -0.27 -0.42 -0.45 -0.04 -0.54 0.39 0.40
Enterprise Value (EV)		 4.77 7.32 0.35 1.45 0.52 -0.98 -0.77 -0.53 -0.42 5.18 9.97
Market Capitalization		 7.91 8.80 2.80 3.70 2.94 1.24 1.02 0.97 2.44 7.23 12
Book Value per Share		 $0.60 $0.33 $0.50 $0.32 $0.22 $0.21 $0.19 $0.19 $0.21 $0.23 $0.22
Tangible Book Value per Share		 $0.60 $0.33 $0.50 $0.32 $0.22 $0.21 $0.19 $0.19 $0.21 $0.23 $0.22
Total Capital		 3.55 2.21 3.57 3.03 2.53 2.50 2.40 2.21 2.42 2.71 3.20
Total Debt		 0.10 0.11 0.24 0.15 0.08 0.09 0.19 0.12 0.06 0.07 0.18
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -3.14 -1.48 -2.46 -2.24 -2.42 -2.22 -1.79 -1.50 -2.86 -2.05 -2.20
Capital Expenditures (CapEx)		 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.21 0.45 0.73 0.50 -0.03 0.16 0.37 0.57 -0.51 0.50 0.76
Debt-free Net Working Capital (DFNWC)		 3.44 2.04 3.43 2.89 2.46 2.46 2.35 2.18 2.41 2.62 3.14
Net Working Capital (NWC)		 3.35 1.93 3.19 2.74 2.38 2.38 2.16 2.06 2.35 2.55 2.96
Net Nonoperating Expense (NNE)		 0.44 0.42 0.12 0.15 0.14 0.02 0.06 0.04 -0.05 0.00 0.00
Net Nonoperating Obligations (NNO)		 -3.14 -1.48 -2.46 -2.24 -2.42 -2.22 -1.79 -1.50 -2.86 -2.05 -2.20
Total Depreciation and Amortization (D&A)		 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 3.40% 6.30% 9.43% 6.22% -0.42% 1.96% 4.92% 7.83% -6.74% 6.17% 8.46%
Debt-free Net Working Capital to Revenue		 56.66% 28.86% 44.27% 36.23% 30.37% 30.56% 31.28% 30.17% 31.51% 32.42% 35.06%
Net Working Capital to Revenue		 55.03% 27.24% 41.17% 34.32% 29.44% 29.48% 28.76% 28.56% 30.69% 31.53% 33.06%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.22) ($0.21) ($0.06) ($0.01) ($0.04) ($0.01) ($0.02) ($0.01) $0.02 $0.02 $0.02
Adjusted Weighted Average Basic Shares Outstanding		 6.50M 6.60M 7.26M 7.55M 11.59M 11.94M 11.94M 11.85M 11.94M 13.18M 14.19M
Adjusted Diluted Earnings per Share		 ($0.22) ($0.21) ($0.06) ($0.01) ($0.04) ($0.01) ($0.02) ($0.01) $0.02 $0.02 $0.02
Adjusted Weighted Average Diluted Shares Outstanding		 6.50M 6.60M 7.26M 7.55M 11.59M 11.94M 11.94M 11.85M 12.78M 13.55M 15.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.42M 6.61M 8.97M 11.31M 11.34M 11.34M 11.34M 11.34M 11.34M 13.84M 13.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.01 -0.97 -0.30 -0.35 -0.33 -0.04 -0.16 -0.09 0.13 0.18 0.21
Normalized NOPAT Margin		 -57.68% -49.41% -13.32% -17.50% -17.84% -2.27% -9.63% -5.48% 5.88% 7.35% 8.21%
Pre Tax Income Margin		 -82.58% -70.58% -18.53% -25.14% -25.42% -3.27% -13.38% -7.76% 10.60% 10.45% 11.72%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -354.17 -372.85 -189.28 -90.75 -146.59 -16.37 -121.87 -31.71 77.57 113.47 221.73
NOPAT to Interest Expense		 -247.92 -260.99 -132.50 -63.53 -102.61 -11.46 -85.31 -22.20 77.57 113.47 254.99
EBIT Less CapEx to Interest Expense		 -355.55 -374.32 -189.28 -90.75 -146.59 -16.37 -121.87 -31.74 77.57 113.47 221.73
NOPAT Less CapEx to Interest Expense		 -249.30 -262.47 -132.50 -63.53 -102.61 -11.46 -85.31 -22.22 77.57 113.47 254.99
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Syra Health’s latest results show a meaningful improvement in reported profitability. Revenue increased to $2.39 million in Q2 2026, up 5.3% from $2.27 million in Q1 2026 and 23.0% from the restated $1.95 million in Q2 2025. Gross profit rose to $1.07 million, while the gross margin improved to approximately 44.5%, compared with 42.7% in Q1 2026 and 38.7% in Q2 2025.

The company also reported operating income of $251,571 and net income of $250,242 in Q2 2026. This follows operating income of $190,983 and net income of $240,979 in Q1, and contrasts with net losses in every reported quarter from Q2 2024 through Q4 2025. However, the earnings improvement should be monitored for durability because Q1 benefited from $52,458 of interest and investment income, while Q2 recorded only $888.

Cash generation was less encouraging. Operating activities used $718,762 in Q2 2026 after generating $1.36 million in Q1. The swing was primarily driven by a $990,840 use of operating capital, including a substantial increase in accounts receivable. Cash and equivalents declined to $2.12 million from $2.92 million at the end of Q1, despite the company remaining well-capitalized relative to its current liabilities.

  • Revenue has grown sequentially and year over year, reaching $2.39 million in Q2 2026.
  • Gross margin improved to approximately 44.5%, the strongest margin among the recent comparable quarters provided.
  • Syra Health produced positive operating income and net income for the second consecutive quarter, a significant improvement from losses during 2024 and 2025.
  • Total current liabilities fell to $1.20 million from $1.58 million in Q1 2026, while short-term debt declined to $71,694 from $188,899 in Q3 2025.
  • Liquidity remains solid on the latest balance sheet: current assets of $3.75 million exceeded current liabilities by roughly 3.1 times.
  • Accounts receivable increased to $1.47 million from $869,132 in Q1, which supported revenue growth but contributed to the sharp decline in operating cash flow.
  • Current deferred revenue declined to $505,886 from $750,524 in Q1, potentially reducing near-term obligations to deliver previously billed services, although the effect on future revenue is uncertain.
  • The company has minimal capital spending and a small fixed-asset base, suggesting a relatively asset-light operating model but also limited tangible asset support.
  • Q2 operating cash flow was negative $718,762, meaning reported earnings did not translate into positive cash generation during the quarter.
  • Share dilution remains a concern: basic weighted-average shares increased to 13.18 million in Q2 from 11.94 million in Q1, while retained earnings remained deeply negative at $(9.23) million.

Overall, the statements indicate that Syra Health is moving toward operational profitability, with improving revenue, margins and balance-sheet liquidity. Retail investors should nevertheless focus on whether the company can convert earnings into recurring operating cash flow and maintain its recent profitability without relying on working-capital movements or additional equity issuance. Several prior-period figures were restated, so historical comparisons should be interpreted with care.

11/13/26 11:05 AM ETAI Generated. May Contain Errors.

Syra Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Syra Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Syra Health's net income appears to be on an upward trend, with a most recent value of -$896.33 thousand in 2025, rising from -$2.12 million in 2022. The previous period was -$3.76 million in 2024.

Syra Health's total operating income in 2025 was -$904.32 thousand, based on the following breakdown:
  • Total Gross Profit: $2.49 million
  • Total Operating Expenses: $3.39 million

Over the last 3 years, Syra Health's total revenue changed from $5.62 million in 2022 to $7.23 million in 2025, a change of 28.6%.

In the past 10 quarters, Syra Health's cash and equivalents has ranged from $1.59 million in Q2 2024 to $3.24 million in Q1 2024, and is currently $2.38 million as of their latest financial filing in Q3 2026.

Syra Health had total debt of $116.39 thousand at the end of 2025, a 23.9% decrease from 2024, and a 84.5% decrease since 2022.

Over the last 3 years, Syra Health's book value per share changed from 0.23 in 2022 to 0.19 in 2025, a change of -20.8%.


Related Companies

Financial statements for NASDAQ:SYRA last updated on 11/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...
USA Capital Gold | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel